Endometrioma and Hemorrhagic Ascites Mimicking Ovarian Cancer: Case Report

An ovarian endometrioma complicated by hemorrhagic ascites can clinically and radiologically mimic advanced ovarian malignancy, presenting a formidable diagnostic challenge for clinicians. This rare presentation requires rigorous histological evaluation, thorough biomarker assessment, and careful multidisciplinary management to avoid unnecessary radical surgical interventions.

Medical literature occasionally documents unusual presentations of benign gynecological conditions that closely simulate aggressive oncological pathologies. A recent clinical case published in Cureus details a striking instance of an endometrioma accompanied by hemorrhagic ascites—the accumulation of blood-stained fluid in the peritoneal cavity—initially suspected to be a malignant ovarian neoplasm. For practicing clinicians, navigating these diagnostic overlaps requires a deep understanding of pelvic pathology, advanced imaging modalities, and biochemical markers.

In Plain English: The Clinical Takeaway

• The Mimicry: Benign chocolate cysts of the ovary (endometriomas) can sometimes leak or rupture, shedding blood into the abdomen and causing fluid buildup (ascites) that mimics advanced cancer.
• The Diagnostic Hurdle: Standard imaging tools like ultrasound and CT scans may show elevated tumor markers and peritoneal fluid, making it difficult to differentiate from epithelial ovarian cancer prior to surgery.
• The Clinical Resolution: Definitive diagnosis relies on pathological examination of tissue biopsies or surgical specimens, underscoring the importance of avoiding premature radical interventions when benign etiologies are possible.

Pathophysiological Mechanisms and Diagnostic Dilemmas

Endometriosis affects roughly 10% of reproductive-age women globally, characterized by the presence of endometrial-like tissue outside the uterine cavity. When this tissue forms localized cysts on the ovaries, known as endometriomas, they can undergo spontaneous rupture or micro-perforations. The extrusion of old blood and cellular debris into the peritoneal cavity incites an inflammatory response. According to clinical studies indexed in PubMed, this peritoneal irritation can lead to significant fluid exudation, manifesting clinically as ascites.

When hemorrhagic ascites is detected alongside a complex adnexal mass, oncologists and gynecological surgeons immediately suspect ovarian malignancy, particularly epithelial ovarian cancer or borderline tumors. Serum tumor markers such as CA-125 are frequently elevated in both advanced endometriosis and ovarian cancer. This elevation destroys the specificity of standard blood tests. As noted in clinical reviews published by the Journal of Minimally Invasive Gynecology, CA-125 levels in patients with massive endometrioma-associated ascites can reach values typically seen in stage III or IV malignancies, compounding the diagnostic confusion.

Diagnostic Comparison: Endometrioma with Hemorrhagic Ascites vs. Epithelial Ovarian Cancer

Clinical Feature	Endometrioma with Hemorrhagic Ascites	Epithelial Ovarian Cancer
Primary Patient Age	Typically premenopausal or early perimenopausal	More common in postmenopausal women
CA-125 Serum Levels	Often moderately to severely elevated	Consistently elevated, often progressively rising
Peritoneal Fluid Characteristics	Hemorrhagic, inflammatory cell infiltrate	Malignant cells present on cytology
Definitive Diagnostic Test	Histopathological confirmation of benign endometriosis	Histopathological confirmation of malignancy

Geographic Healthcare Disparities and Public Health Impact

The management of complex pelvic masses varies significantly across global healthcare infrastructures. In the United States and Western Europe, advanced laparoscopic techniques and rapid frozen-section histopathology during exploratory surgery allow medical teams to evaluate questionable peritoneal fluid and adnexal masses intraoperatively. This capability minimizes the risk of executing extensive staging surgeries for benign conditions.

Conversely, in resource-limited settings tracked by the World Health Organization (WHO), access to specialized gynecological oncologists and immediate intraoperative pathology services is severely constrained. Patients presenting with hemorrhagic ascites and elevated tumor markers in these regions face a higher statistical probability of undergoing radical staging procedures, including total abdominal hysterectomy and bilateral salpingo-oophorectomy, due to the presumptive diagnosis of malignancy. Public health initiatives must prioritize improving diagnostic accuracy and expanding access to tertiary care centers to mitigate these disparities.

Contraindications & When to Consult a Doctor

Patients diagnosed with persistent pelvic masses, unexplained abdominal distension, or rising tumor markers must be evaluated by a multidisciplinary team.

• Contraindications for Conservative Management: Rapidly growing pelvic masses, highly suspicious ultrasound morphology (such as solid papillary projections with high-velocity internal blood flow), and significantly elevated risk indices preclude watchful waiting.
• When to Seek Urgent Medical Care: Severe, acute pelvic or abdominal pain accompanied by nausea, vomiting, or hemodynamic instability indicates potential cyst rupture, ovarian torsion, or acute internal hemorrhage, requiring immediate emergency department evaluation.

Future Trajectory in Gynecological Diagnostics

Distinguishing benign inflammatory mimics from malignant neoplasms remains one of the most delicate tasks in clinical medicine. As molecular diagnostics and biomarker panels evolve, the medical community moves closer to reducing false-positive cancer diagnoses caused by benign conditions like hemorrhagic endometriomas. Emphasizing cautious, evidence-based surgical exploration ensures that patients receive accurate staging while preserving reproductive potential wherever clinically appropriate.